Last reviewed · How we verify
DA-302168S
DA-302168S is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
DA-302168S is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | DA-302168S |
|---|---|
| Sponsor | Chendu DIAO Pharmaceutical Group CO., LTD. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, DA-302168S reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects (PHASE2)
- The Food Effect on Pharmacokinetics of DA-302168S (PHASE1)
- A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects (PHASE1)
- Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-302168S CI brief — competitive landscape report
- DA-302168S updates RSS · CI watch RSS
- Chendu DIAO Pharmaceutical Group CO., LTD. portfolio CI